Vanguard Mortgage-Backed Securities Getting Very Oversold
Vanguard Mortgage-Backed Securities RSI Analysis: The RSI for Vanguard Mortgage-Backed Securities (VMBS) is at 29.2, indicating potential exhaustion of recent selling pressure, compared to the S&P 500's RSI of 49.6.
Current Trading Performance: VMBS shares are trading at $45.53, down about 0.3% for the day, with a 52-week range between $43.275 and $47.59.
Trade with 70% Backtested Accuracy
Analyst Views on VMBS
About the author
Trump Directs Representatives to Purchase $200 Billion in Mortgage Bonds; Impact on MBS ETFs.
- Trump's Initiative: President Donald Trump has initiated efforts to combat high mortgage rates.
- Goal of the Initiative: The aim is to make home buying more affordable for potential buyers.
Impact of Trump's Mortgage Bond Purchase Plan on Interest Rates
- Trump's Initiative: President Donald Trump has initiated efforts to combat high mortgage rates.
- Goal of the Initiative: The aim is to make home buying more affordable for potential buyers.
Vanguard Mortgage-Backed Securities ETF announces monthly payout of $0.1652
Vanguard Mortgage-Backed Securities ETF (VMBS)
Current Dividend: The ETF has declared a dividend of $0.1652, which is payable on September 4, 2023, to shareholders of record as of September 2, 2023. The ex-dividend date is also September 2, 2023.
Yield Information: As of August 27, the 30-Day SEC Yield stands at 4.09%, indicating a solid return for investors in the current market environment.
Market Conditions
Mortgage Rates: Mortgage rates have reached a ten-month low, contributing to an increase in purchase demand, which is a positive sign for the housing market.
Rate Stability: Mortgage rates have remained flat week-over-week, suggesting stability in the market that could encourage further investment in mortgage-backed securities.
Investment Insights
Seeking Alpha Rating: The Vanguard Mortgage-Backed Securities Index Fund ETF Shares have received a Quant Rating from Seeking Alpha, which may provide insights into its performance and investment potential.
Dividend Scorecard: The ETF's dividend scorecard reflects its performance in terms of dividend payments, which is an important metric for income-focused investors.
UWM was the top mortgage originator last year - report
Top Mortgage Lenders of 2024: UWM Holdings led the mortgage lending market in 2024 with $139.72 billion in funded loans, followed by Rocket Mortgage at $97.56 billion and JPMorgan Chase at $50.65 billion.
Market Trends: Nonbank lenders increased their market share in mortgage lending while commercial banks saw a decline, as highlighted in the S&P Global Market Intelligence report.
VMBS, XDOC: Big ETF Outflows
ETF Outflows: The XDOC ETF experienced the largest outflow, losing 50,000 units, which is a 33.3% decrease in outstanding units compared to the previous week.
Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
VMBS, BBC: Big ETF Outflows
ETF Outflows: The Virtus LifeSci Biotech Clinical Trials ETF experienced the largest outflow, losing 300,000 units, which is a 40.0% decline compared to the previous week.
Stock Performance: In morning trading, Xeris Biopharma Holdings fell by approximately 8.2%, while Soleno Therapeutics decreased by about 5.8%.
Trump Directs Representatives to Purchase $200 Billion in Mortgage Bonds; Impact on MBS ETFs.
- Trump's Initiative: President Donald Trump has initiated efforts to combat high mortgage rates.
- Goal of the Initiative: The aim is to make home buying more affordable for potential buyers.
Impact of Trump's Mortgage Bond Purchase Plan on Interest Rates
- Trump's Initiative: President Donald Trump has initiated efforts to combat high mortgage rates.
- Goal of the Initiative: The aim is to make home buying more affordable for potential buyers.
Vanguard Mortgage-Backed Securities ETF announces monthly payout of $0.1652
Vanguard Mortgage-Backed Securities ETF (VMBS)
Current Dividend: The ETF has declared a dividend of $0.1652, which is payable on September 4, 2023, to shareholders of record as of September 2, 2023. The ex-dividend date is also September 2, 2023.
Yield Information: As of August 27, the 30-Day SEC Yield stands at 4.09%, indicating a solid return for investors in the current market environment.
Market Conditions
Mortgage Rates: Mortgage rates have reached a ten-month low, contributing to an increase in purchase demand, which is a positive sign for the housing market.
Rate Stability: Mortgage rates have remained flat week-over-week, suggesting stability in the market that could encourage further investment in mortgage-backed securities.
Investment Insights
Seeking Alpha Rating: The Vanguard Mortgage-Backed Securities Index Fund ETF Shares have received a Quant Rating from Seeking Alpha, which may provide insights into its performance and investment potential.
Dividend Scorecard: The ETF's dividend scorecard reflects its performance in terms of dividend payments, which is an important metric for income-focused investors.
UWM was the top mortgage originator last year - report
Top Mortgage Lenders of 2024: UWM Holdings led the mortgage lending market in 2024 with $139.72 billion in funded loans, followed by Rocket Mortgage at $97.56 billion and JPMorgan Chase at $50.65 billion.
Market Trends: Nonbank lenders increased their market share in mortgage lending while commercial banks saw a decline, as highlighted in the S&P Global Market Intelligence report.
VMBS, XDOC: Big ETF Outflows
ETF Outflows: The XDOC ETF experienced the largest outflow, losing 50,000 units, which is a 33.3% decrease in outstanding units compared to the previous week.
Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
VMBS, BBC: Big ETF Outflows
ETF Outflows: The Virtus LifeSci Biotech Clinical Trials ETF experienced the largest outflow, losing 300,000 units, which is a 40.0% decline compared to the previous week.
Stock Performance: In morning trading, Xeris Biopharma Holdings fell by approximately 8.2%, while Soleno Therapeutics decreased by about 5.8%.
